Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431599 | 0.92 | PTGS2 (0.43) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL27852642 | 0.82 | PTGS2 (0.41) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL592383 | 0.79 | PTGS2 (0.46) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3404636 | 0.77 | PTGS2 (0.42) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL1839980 | 0.77 | PTGS2 (0.42) | PTGS2MTNR1AMTNR1BHTR2C | |
| Hydrochloric Acid SCHEMBL20562399 | 0.76 | PTGS2 (0.42) | PTGS2MTNR1AMTNR1B | |
| SCHEMBL1837381 | 0.76 | MTNR1A (0.36) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3618041 | 0.74 | PTGS2 (0.43) | PTGS2MTNR1AMTNR1B | |
| SCHEMBL3412295 | 0.73 | PTGS2 (0.44) | PTGS2MTNR1AMTNR1BNNMTHTR2C | |
| SCHEMBL592375 | 0.73 | PTGS2 (0.44) | PTGS2MTNR1AMTNR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466168-B2 | Tricyclic alkylaminomethyloxazolidinone derivatives | Actellon Pharmaceuticals Ltd. (CH) | 2013-06-18 | — | — | US | disclosed |
| EP-2321307-B1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20110136795-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. | 2011-06-09 | — | — | US | disclosed |
| EP-2321307-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010015985-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136795-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | PYM1, Q6ZSR9, O60361 | PTGS2 2436/4885MTNR1A 438/4885MTNR1B 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.